Crescita Research Development from 2010 to 2026

CTX Stock  CAD 0.49  0.02  4.26%   
Crescita Therapeutics Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to drop to about 552.3 K. During the period from 2010 to 2026, Crescita Therapeutics Research Development quarterly data regression pattern had sample variance of 11.5 T and median of  1,112,000. View All Fundamentals
 
Research Development  
First Reported
2015-03-31
Previous Quarter
141 K
Current Value
138 K
Quarterly Volatility
1.3 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.
Evaluating Crescita Therapeutics's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.

Latest Crescita Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of Crescita Therapeutics over the last few years. It is Crescita Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Crescita Research Development Regression Statistics

Arithmetic Mean3,342,455
Geometric Mean1,872,303
Coefficient Of Variation101.29
Mean Deviation3,103,326
Median1,112,000
Standard Deviation3,385,515
Sample Variance11.5T
Range8.5M
R-Value(0.85)
Mean Square Error3.4T
R-Squared0.72
Significance0.000015
Slope(570,492)
Total Sum of Squares183.4T

Crescita Research Development History

2026552.3 K
2025581.4 K
2024646 K
2023699 K
2022609 K
2021634 K
20201.1 M

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as Research Development, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development581.4 K552.3 K

Pair Trading with Crescita Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crescita Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crescita Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Crescita Stock

  0.46UBER Uber CDRPairCorr
  0.36ABBV AbbVie CDRPairCorr
The ability to find closely correlated positions to Crescita Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crescita Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crescita Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crescita Therapeutics to buy it.
The correlation of Crescita Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crescita Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crescita Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crescita Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.